PROTOCOL NIDA-CTN-0065-Ot


Evaluation of Drug Screening Implementation in Primary Care

Principal Investigator
Katharine Bradley, MD, MPH
Group Health Research Institute
bradley.k@ghc.org

Recent trials of screening and brief intervention for drug use have no demonstrated benefit compared to screening alone. However, the value of screening for drug use, compared to no screening, has not been evaluated. Screening for drug use may identify patients with drug use disorders who might need more intensive treatments than brief intervention. In states where marijuana use is now legal for recreation, as well as medical uses, clinicians want to be aware of and assess risks of marijuana use. Further, little is known about the predictive validity of screens for marijuana and/or drug use/misuse for subsequent adverse health outcomes. To that end, this study seeks to evaluate implementation of drug screening in primary care to: 1) describe rates of drug and marijuana screening, and positive screens, as well as barriers and facilitators to population-based screening; 2) assess changes in rates of assessment and identification; and 3) assess whether drug and marijuana use is associated with increased subsequent urgent care, ED, and hospitalization.

RELATED RESOURCES

snowflake

Publications about CTN-0065-Ot

NIDA protocol page


NODES & CTPs SEARCH LINK
Health Systems (Lead) search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 4/2016 -- http://ctndisseminationlibrary.org/protocols/ctn0065ot.htm
info@ctndisseminationlibrary.org